|  |  |
| --- | --- |
|  | **TGCT dose cohorts** |
|  | **Cohort 5****n = 8**a | **Cohort 8****n = 12** | **Cohort 9****n = 12** | **Total****N = 32** |
| **Loading dose** | 30 mg QD x 5 days | 30 mg QD x 3 days | 20 mg QD x 3 days |  |
| **Dose** | 30 mg twice weekly | 10 mg QD | 6 mg QD |  |
| **Best overall response, n (%)**b |  |  |  |  |
| Complete response | 1 (13) | 0 | 0 |  1 (3) |
| Partial response | 5 (63) | 9 (75) | 7 (58) | 21 (66) |
| Stable disease | 2 (25) | 3 (25) | 5 (42) | 10 (31) |
| **Objective response rate, n (%)** | 6 (75) | 9 (75) | 7 (58) | 22 (69) |
| Percentages are rounded and may not equal the whole.a1 patient does not have central read data and was included as a stable disease assessment.bAssessed using RECIST v1.1 by independent radiologic review; includes all available follow-ups. |